摘要
Dear Editor,We read with great interest the study by Cheng et al[1], which assessed the two-year outcomes in 30(36 eyes) diabetic macular edema(DME) patients treated with intravitreal conbercept(Lumitin;Chengdu Kanghong Biotech Xo, Ltd, China;IVC) for 3 mo.